Aspire Biopharma Holdings Inc.

About Aspire Biopharma Holdings Inc.

Aspire Biopharma is focused on revolutionizing healing and redefining medicine through innovative drug delivery methods. Their mission is to enhance medication efficacy, promote faster healing, and address the growing needs of the community with no-harm medicine for pain management and inflammation therapeutics. They aim to impact the opioid crisis with next-generation absorption technologies.

Products & Services

Sublingual Aspirin Product:A soon-to-be-released product designed for sublingual administration, offering fast-acting relief by bypassing the digestive tract.

BUZZ BOMB(TM) Pre-Workout Supplement:A pre-workout supplement recently launched at major fitness conventions and through an e-commerce platform.

Novel Soluble Formulation Technology:A disruptive technology for drug delivery that allows instant absorption in the mouth, targeting pain and inflammation, and applicable to various drugs like analgesics, erectile dysfunction, and traumatic brain injury treatments.

Specialties

Drug Delivery Technology Nano Technology Drug Formulation Sublingual Absorption Pain Management Inflammation Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 21000000 MR: - FA: $21.0 million FAN: 21000000	D: 2026-02-11 FD: 2026-02-11	1 investors
2	RT: Debt (Senior Secured Convertible Debenture) T: - FT: Debt (Senior Secured Convertible Debenture)	A: 3000000 MR: - FA: $3.0 million FAN: 3000000	D: 2025-02-20 FD: 2025-02-20	-

Private Placement Latest

2026-02-11

$21.0M

1 investor (Pro only)

Debt (Senior Secured Convertible Debenture) 2025-02-20

$3.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News